Each year I’m honored to attend ASH with the IMF. I’ve been a myeloma survivor for 16 years and am encouraged to continue to share all the good news from ASH. When I first attended ASH with the IMF about 10 years ago, there were not nearly as many trials as we have now. It […]
Today’s events began with 9:30 a.m. education program on 1) managing Newly Diagnosed High-Risk (HR) Multiple Myeloma patients 2) Sequencing treatments, and 3) the role of stem cell transplant (SCT) and maintenance. Dr Angela Dispenzieri spoke on the first topic, and she reminded the audience that “High-Risk” doesn’t just mean cytogenetic factors like del(17p), but […]
